Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.51 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27643278 | 0.88 | PTGER2 (0.56) | CNR2 | |
| SCHEMBL5043170 | 0.88 | PTGER2 (0.56) | CNR2 | |
| SCHEMBL2396450 | 0.85 | ALDH1A1 (0.48) | CNR2ALDH1A1 | |
| SCHEMBL1471278 | 0.85 | CNR2 (0.53) | CNR2ALDH1A1MAPK1KMT2ATDP1 | |
| SCHEMBL5726069 | 0.84 | ALDH1A1 (0.47) | CNR2ALDH1A1 | |
| SCHEMBL12749297 | 0.83 | PTGER2 (0.57) | ALDH1A1MAPK1KMT2ATDP1 | |
| SCHEMBL14569238 | 0.81 | S1PR1 (0.52) | ALDH1A1 | |
| SCHEMBL26313799 | 0.81 | CA9 (0.57) | CNR2KEAP1NFE2L2 | |
| SCHEMBL15677741 | 0.80 | RXFP1 (0.63) | CNR2ALDH1A1KMT2ATDP1 | |
| SCHEMBL6571433 | 0.80 | CNR2 (0.63) | CNR2ALDH1A1KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442702-B2 | Treatment of bone disorders; carboxy derivatives | PFIZER INC. (US) | 2008-10-28 | — | — | US | disclosed |
| EP-1021410-B1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER (US) | 2006-12-27 | — | — | EP | disclosed |
| CN-1859903-A | Use of EP2 selective receptor agonists in medical treatment | PFIZER PROD INC (US) | 2006-11-08 | — | — | CN | disclosed |
| EP-1601351-A1 | USE OF EP2 SELECTIVE RECEPTOR AGONISTS IN MEDICAL TREATMENT | Pfizer Products Inc. (US) | 2005-12-07 | — | — | EP | disclosed |
| US-20050203086-A1 | Methods of treatment using an EP2 selective receptor agonist | PFIZER INC. | 2005-09-15 | — | — | US | disclosed |
| CN-1211367-C | Prostaglandin agonists and their use to treat bone disorders | PFIZER (US) | 2005-07-20 | — | — | CN | disclosed |
| CN-1566096-A | Prostaglandin agonists and their use to treat bonedisorders | PFIZER (US) | 2005-01-19 | — | — | CN | disclosed |
| WO-2004078169-A1 | USE OF EP2 SELECTIVE RECEPTOR AGONISTS IN MEDICAL TREATMENT | PFIZER PRODUCTS INC. (US) | 2004-09-16 | — | — | WO | disclosed |
| US-20030078261-A1 | Prostaglandin agonists | CAMERON KIMBERLY O (US) | 2003-04-24 | — | — | US | disclosed |
| US-6498172-B1 | (3-(((4-TERT-BUTYL-BENZYL)-(PYRIDINE-3-SULFONYL)-AMINO)-METHYL) -PHENOXY)-ACETIC ACID OR SALT; TREATING SUCH AS OSTEOPOROSIS | PFIZER INC. | 2002-12-24 | — | — | US | disclosed |
| CN-1275123-A | Prostaglandin agonists and their use to treat bone disorders | PFIZER (US) | 2000-11-29 | — | — | CN | disclosed |
| EP-1021410-A1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER INC. (US) | 2000-07-26 | — | — | EP | disclosed |
| WO-1999019300-A1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER INC. (US) | 1999-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203086-A1 | Methods of treatment using an EP2 selective receptor agonist | PTGER2, PTGES2, PTGFR | CNR2 244/4885ALDH1A1 3293/4885MAPK1 2626/4885 |
| US-20030078261-A1 | Prostaglandin agonists | PTGER1, PTGER4, PTGIR | CNR2 373/4885ALDH1A1 1987/4885MAPK1 2397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.